acute heart failure
Conditions
Interventions
Healthy control group:None
Acute Heart Failure Subgroup 1:Treat with Levosimendan
Acute Heart Failure Subgroup 2:Treat with Dobutamine
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.All patients meet the diagnostic criteria for acute ST-segment elevation myocardial infarction, and suffer from acute myocardial infarction for the first time; 2.Open infarct-related stenosis or blockage of coronary arteries; 3.At least 3 of the 16 left ventricular segments showed signs of reduced ventricular wall motion; 4.Clinical acute heart failure is defined as dyspnea at rest during screening and at least one of the following signs within 48 hours after PCI: pulmonary edema, signs of significant pulmonary congestion on chest X-ray, requiring continuous positive pressure ventilation or mechanical ventilation , Still have symptoms of congestion or need intravenous diuretic treatment after volume therapy; 5.There is no restriction on gender between 20 and 80 years old; 6.Healthy recruiters may be diagnosed with acute myocardial infarction with or without acute heart failure; 7.Volunteer to participate in the study. Other criteria of the cardiogenic shock subgroup: 1.The systolic blood pressure (SBP) is less than 90 mmHg for more than 30 minutes or the use of catecholamine drugs is maintained between 90 and 100 mmHg; 2.Signs of persistent tissue and organ hypoperfusion: persistent oliguria (urine volume 2.0mmol/L, etc.
Exclusion criteria
Exclusion criteria: 1.Heart rate beats greater than 120 beats/min; 2.Medical history of previous PCI, septic shock, malignant tumor, acute respiratory distress syndrome, severe renal insufficiency (creatinine > 450 µmol/L), severe liver failure, autoimmune disease (systemic lupus erythematosus, etc.), Obvious mechanical obstruction of the outflow tract; 3.Allergic to the study drug or one of the drugs; 4.Severe anemia (hemoglobin < 7 g/dl) or pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical score;Proteomics testing;RNA m6A methylation detection;NYHA classification of cardiac function;Minnesota Cardiac Insufficiency Quality of Life Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood biochemical indexes;12-lead ECG;Echocardiography(automatic function imaging, AFI));Chest CT;Cardiac magnetic resonance; | — |
Countries
China
Contacts
Public ContactLi Xiaodong
Shengjing Hospital of China Medical University
Outcome results
None listed